Revenue segments as reported by the company.

Diabetes

Oncology

Immunology

Neuroscience

Other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Marketing, selling and administrative

Acquired in-process research and development

Asset impairment, restructuring and other special charges

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Eli Lilly

Cialis, ia a competitor to Pfizer's blockbuster Viagra for erectile dysfunction. Cialis maintains an active period of 36 hours.

Cialis

Cymbalta is a serotonin-norepinephrine reuptake inhibitor used predominantly in the treatment of major depressive disorders and generalized anxiety disorder, ranks with Prozac as one of the most financially successful pharmaceuticals in industry history. It is also used in the treatment of fibromyalgia, neuropathy, chronic pain and osteoarthritis.

Cymbalta

Gemzar is a treatment of pancreatic cancer. Gemzar is commonly used in the treatment of pancreatic cancer, usually in coordination with 5-FU chemotherapy and radiology. Gemzar also is routinely used in the treatment of non-small cell lung cancer.

Gemzar

Methadone is an analgesic used frequently in the treatment of heroin, opium and other opioid and narcotic drug addictions.

Methadone

Prozac was one of the first therapies in its class to treat clinical depression by blocking the uptake of serotonin within the human brain. It is prescribed to more than fifty-four million people worldwide.

Prozac

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Eli Lilly reports robust Q4 earnings, eyes growth in innovative therapies

Eli Lilly's Q4 2022 earnings call highlighted strong financial performance, pipeline advancements, and strategic initiatives for future growth.
The company's focus on innovation, FDA approvals, and market expansion underscores its commitment to addressing unmet medical needs and driving shareholder value.
Challenges in physician education, obesity treatment development, and market access present areas for strategic focus and investment for sustained growth.
Opportunities in expanding manufacturing capacity, engaging with payers, and capitalizing on consumer interest in obesity treatments position Lilly for continued success in 2023.

Eli Lilly reports robust Q1 growth amidst capacity challenges

Eli Lilly's Q1 2023 performance reflects strong revenue growth and strategic investments in new products and facilities.
While facing challenges in capacity and supply pressure, the company's focus on pipeline advancements and market opportunities positions it for future growth.
Opportunities in international markets, cardiovascular trials, and product promotion present avenues for continued expansion and revenue growth.
Overall, Eli Lilly's financial performance, product strengths, and strategic initiatives demonstrate a resilient and growth-focused approach.

Eli Lilly reports robust Q2 earnings, eyes growth through innovation

Eli Lilly's Q2 earnings call showcased strong financial performance, revenue growth, and advancements in its pipeline, driven by key products and strategic investments.
The company faces challenges in managing increased expenses, supply chain constraints, and regulatory considerations, requiring strategic decision-making and operational agility.
Opportunities lie in expanding market access, leveraging innovative treatments like tirzepatide, and enhancing manufacturing capabilities to drive future growth and competitive advantage.
Overall, Lilly's focus on innovation, market expansion, and addressing health needs positions it well for sustained growth and leadership in the pharmaceutical industry.

Eli Lilly posts robust Q3 results, eyes expansion and commercial growth

Eli Lilly (LLY) showcased strong financial performance and pipeline advancements in Q3 2023.
Challenges include supply restrictions and pricing decisions, but opportunities lie in expansion plans and commercial coverage ramp-up.
Investors advised to focus on guidance range for insights into 2024 expectations.

Eli Lilly posts robust Q4 results, eyes global expansion opportunities

Eli Lilly's strong financial performance in Q4 2023, driven by revenue growth and operational efficiency, sets a solid foundation for future growth.
The company's strategic acquisitions, global expansion plans, and focus on innovation position it well for continued success and market leadership.
Challenges in drug development and manufacturing require careful navigation, but opportunities in new drug trials and market expansion offer avenues for growth.
Overall, Eli Lilly's 2023 was marked by productivity and anticipation of sustained momentum in 2024, reflecting a positive outlook for the company.

Eli Lilly reports robust Q1 growth, eyes pipeline opportunities

Eli Lilly's Q1 performance showcased strong revenue growth, driven by new products and global market expansion.
While facing challenges like low Zepbound volume and manufacturing complexities, Lilly's strengths in innovation and market presence position it well for growth.
Opportunities in pipeline advancements, differentiation in drug portfolios, and potential Alzheimer's treatments signal a promising future for the company.
Overall, Eli Lilly's strategic focus on growth, innovation, and market expansion sets a positive trajectory for continued success.

Eli Lilly reports stellar Q3 results, eyes global expansion opportunities

Eli Lilly's Q3 performance reflects robust revenue growth, driven by new products and strategic investments, positioning the company for continued success.
Key pipeline advancements and revenue guidance raise optimism for future growth, with a focus on global scaling and market expansion initiatives.
Challenges in patient adherence and treatment efficacy are being addressed, while opportunities in market penetration and revenue growth are actively pursued.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Lilly's Alzheimer's treatment could reach blockbuster status by 2025, an analyst said Monday. Eli Lilly stock is trading near a record high.

Eli Lilly's Alzheimer's Drug Is Just Version 1.0. But It's Still On Track For Blockbuster Status, Analyst Says.

Lilly (LLY) expects to launch four new medicines by 2023 end, of which Mounjaro for type II diabetes and cancer drug Jaypirca have already been launched.

Eli Lilly (LLY) Stock Up 18.7% YTD, New Drugs Key to Growth

American Express

bluebird bio

Discover

Goldman Sachs

ImmunoGen

SoFi Technologies

The Regional Bank Fiasco is a classic “Baby with the Bathwater” scenario. Rising rates are great for Insurance companies and “hidden banks”.

Tech Titans Aren't The Only Game In Town, Consider Biotech And, Yes, Financials

Eli Lilly and Company (NYSE:LLY ) Bank of America Securities 2023 Healthcare Conference May 10, 2023 1:00 PM ET Company Participants Patrik Jonsson - Executive Vice President, President-Lilly Immunology, President-Lilly USA & Chief Customer Officer Conference Call Participants Geoff Meacham - BofA Geoff Meacham Okay. Welcome to the second day of the BofA Healthcare Conference.

Eli Lilly and Company (LLY) Presents at Bank of America Securities 2023 Healthcare Conference

Biogen

Two new medicines are going to compete for the Alzheimer's therapy market. Eli Lilly's candidate appears to be more effective, but it isn't approved yet.

These 2 Pharma Stocks Might Face Off Soon -- but They Could Both Win

Axsome Therapeutics

Vertex Pharmaceuticals

Axsome's relatively new approval was only the first step in an exciting growth story. Eli Lilly has a strong pipeline that will help improve its already-solid financial results.

3 Growth Stocks to Buy and Hold

The market is pricing Eli Lilly's stock as if its earnings are going to grow like wild, and they might. Its pipeline could furnish the company with plenty of near-term growth.

Will Eli Lilly Be a Trillion-Dollar Stock by 2030?

Johnson & Johnson

Eli Lilly & Co. was on track Friday to close with a greater market capitalization than Johnson & Johnson for the first time since October 1997, according to Dow Jones Market Data.

Eli Lilly on track to close with a higher market cap than J&J for first time since 1997

Novo Nordisk

Novo Nordisk's Wegovy and Eli Lilly's Zepbound are so far the leaders in the weight-loss drug market, which is estimated to be worth about $150 billion by the early 2030s.

Weight-loss drug developers line up to tap market worth $150 billion

Viking Therapeutics

Viking Therapeutics said on Tuesday its experimental drug helped patients with obesity achieve "significant" weight loss in a mid-stage study.

Drugmakers deepen efforts to tap into booming market for obesity drugs

Eli Lilly's donanemab just proved effective in treating Alzheimer's disease in a pivotal clinical trial. This should be yet another key addition to Eli Lilly's expanding lineup.

Here's What Eli Lilly's Latest Clinical Win Means For Investors

Cigna

CVS Health

Sanofi

UnitedHealth Group

A bipartisan effort to rein in prescription drug prices advanced Thursday as a key U.S. Senate committee approved a bill aimed at reforming pharmacy benefit managers.

Prescription-drug costs in spotlight as pharmacy benefit reform advances in Senate

Trial data show that donanemab may potentially slow the progression of Alzheimer's. The drug candidate has also been effective in reducing amyloid plaque in the brain.

Here's Why Eli Lilly's Alzheimer's Drug Could Be the Real Deal

INDIANAPOLIS , May 11, 2023 /PRNewswire/ -- Loxo@Lilly, the oncology unit of Eli Lilly and Company (NYSE: LLY), today announced that data from its oncology portfolio will be presented at the 2023 European Hematology Association (EHA) Annual Meeting, to be held June 8 – 11, 2023, in Frankfurt, Germany, and virtually. The company-sponsored abstracts include new analyses of clinical data in approved and investigational uses based on the BRUIN Phase 1/2 trial evaluating Jaypirca™ (pirtobrutinib) in patients with B-cell malignancies previously treated with a covalent Bruton's tyrosine kinase (BTK) inhibitor, including mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL).

Loxo@Lilly Announces Details of Presentations at 2023 European Hematology Association (EHA) Annual Meeting

He was the only executive to do so before a Senate Health Committee hearing that also included the CEOs of Novo Nordisk and Sanofi.

Eli Lilly CEO vows not to raise insulin prices again, while Novo Nordisk and Sanofi hedge

The headline inflation figure rose at the slowest rate in more than two years.

Bearish Headwinds Have Evolved to Bullish Tailwinds: This Industry Soars

ROCKVILLIE, Md. and SUZHOU, China, May 9, 2023 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, autoimmune, metabolic, ophthalmology and other major diseases, and Eli Lilly and Company ("Lilly", NYSE: LLY), jointly announced that the National Medical Products Administration (NMPA) of China has approved the supplemental New Drug Application (sNDA) for TYVYT® (sintilimab injection) in combination with bevacizumab and chemotherapy (pemetrexed and cisplatin) in patients with epidermal growth factor receptor (EGFR)-mutated non-squamous non-small cell lung cancer (NSCLC) who progressed after EGFR tyrosine kinase inhibitor (TKI) therapy.

The China NMPA Approves TYVYT® (sintilimab injection) in Combination with Bevacizumab and Chemotherapy in Patients with EGFR-mutated Non-squamous NSCLC who Progressed after EGFR-TKI Therapy

INDIANAPOLIS , May 9, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) has allocated an additional $50 million to its now $300 million Social Impact Venture Capital Portfolio, reflecting the company's commitment to going beyond the medicines it makes to have a positive impact on patients and society through for-profit investments. The portfolio is aligned with Lilly's efforts to combat racial injustice and its effects on Black Americans and historically marginalized communities in the U.S., as well as Lilly 30x30, a global initiative to improve access to quality healthcare for 30 million people living in limited-resource settings annually by 2030.

Lilly's Social Impact Venture Capital Portfolio Poised to Grow to $300 Million with New $50 Million Allocation

After a relatively impressive 2022, the best healthcare dividend stocks have hit a temporary rough patch this year. However, savvy investors shouldn't let this blip deter them from wagering on this defensive sector for income stock opportunities.

3 Dividend Stocks to Buy as the Healthcare Sector Booms in 2023

- First interim Phase 2 data of an IL-23p19 antagonist in pediatric patients - New analysis from the pivotal Phase 3 LUCENT-1 and LUCENT-2 studies INDIANAPOLIS , May 9, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today new investigational data for mirikizumab in patients with moderately to severely active ulcerative colitis (UC) that further support the efficacy and safety seen in previous pivotal studies.  Data presented at Digestive Disease Week® (DDW), held in Chicago from May 6-9, include an oral presentation of an interim analysis of mirikizumab as induction therapy in pediatric patients with moderately to severely active UC from the Phase 2 SHINE-1 study, and a new analysis from LUCENT-1 and LUCENT-2 studies evaluating the relative association of bowel urgency remission on Inflammatory Bowel Disease Questionnaire (IBDQ) scores, which assess the impact of UC on quality of life in adults.

Lilly Discloses First-in-Class, Interim Phase 2 Data in Pediatric Patients and New Analysis from Phase 3 Program in Adult Patients for Mirikizumab in Ulcerative Colitis

Eli Lilly published positive clinical trial results on a weight-loss drug and an early-stage Alzheimer's treatment candidate. Though its Q1 results fell short of analysts' estimates, investors were pleased with management's updated 2023 forecast.

Why Did Eli Lilly Stock Jump 15% in April?

Eli Lilly's near-term outlook is quite favorable. The only major constraint it faces is competition in several drug markets.

Where Will Eli Lilly Be in 3 Years?

The next couple of years will see Eli Lilly's top and bottom lines swell. Its debt load looks like more of a problem than it actually is.

3 Things About Eli Lilly That Smart Investors Know

Bristol-Myers

There are often trade-offs to make when selecting passive income stocks. Eli Lilly's next couple of years will see its revenue burgeon by billions.

Which Is the Better Passive Income Stock, Eli Lilly or Bristol Myers Squibb?

Teladoc

Investors remain puzzled due to persistent macro challenges, continued interest rate hikes, and the regional banking crisis. Given the ongoing uncertainties, sectors that are resilient during economic downturns could offer attractive investment opportunities.

News for Eli Lilly Stock (LLY)